- Tuberculosis (TB) drug discovery: Drug target identification and validation using an integrated genetic, physiological and biochemical approach. This expertise is provided by the MRC/NHLS/UCT Molecular Mycobacteriology Research Unit (MMRU), which also serves as the UCT node of the Department of Science and Technology (DST)/National Research Foundation (NRF) Centre of Excellence for Biomedical TB Research. This laboratory, which was established at UCT in 2011, is located in the Institute of Infectious Disease and Molecular Medicine (IIDMM) and is run jointly by Professor Valerie Mizrahi (Director, IIDMM) and Dr Digby Warner. Research in the MMRU is focused on studying aspects of the physiology and metabolism of Mycobacterium tuberculosis of particular relevance to TB drug discovery and drug resistance. All research in the MMRU that involves the large-scale culturing and genetic manipulation of M. tuberculosis is carried out in a state-of-the-art BSL3 laboratory in the IIDMM which was refurbished in 2010 to accommodate the needs of the MMRU
- Biochemistry: Recombinant protein expression, protein isolation and characterisation, protein-ligand binding using isothermal titration calorimetry, and development of enzyme assays for evaluating inhibitor efficacy
- Computational Chemistry: ADME and permeability predictions, molecular modeling, virtual screening, chemoinformatics
- Our vision is for the Centre to deliver drug candidates for clinical
- A Drug Discovery Centre whose activities mirror those of a start up
biotechnology or a pharmaceutical company.
- Involved in partnerships that allow the Centre to harness the synergies
obtained from working on multiple disease areas.
- Africa’s first integrated drug discovery and development centre.
The Centre aims to bridge the gap between basic and clinical studies,
training a new generation of African scientists with key skills required for
drug discovery and development – integrating medicinal chemistry, biology,
pharmacology as well as drug metabolism and pharmacokinetics (DMPK) studies
as reflected in the processes of Absorption, Distribution, Metabolism and
Excretion (ADME). H3-D also focuses on beneficiation of clinically used
drugs, including generic medicines. Drug beneficiation, amongst other
things, involves selection of the optimum form of a solid drug candidate for
pharmaceutical development and (re)formulation.
Summer officially begins in London in June as Rioja Tapas Fantasticas returns for two days on Saturday 25th and Sunday 26th June 2011. The free event will be held at the same fantastic venue as last year – Potters Fields Park – so grab your friends, come down and enjoy the food, drink and entertainment.
A spectacular variety of red, white and rosé wines from some of Rioja’s most famous vineyards will be available for you to taste as you make your way around the vibrant wine and tapas stalls. Savour a diverse selection of tapas from London’s finest Spanish restaurants who will recreate the famous tapas streets of the Rioja region where you can go from bar to bar sampling a speciality dish and glass of delicious local wine in each.
There will be plenty to entertain – enjoy live Spanish music, cookery demonstrations, wine tasting workshops and wine walks, children’s activities and an unforgettable eating and drinking experience. Purchase your wine glass on entry and receive four tokens which can be exchanged for samples of top class Rioja wines. Sign up for the wine workshops and walks with wine experts Olly Smith and Susy Atkins to learn more about Rioja and discover what tickles your taste buds.